Welcome

Opthea is developing novel biologic inhibitors of angiogenesis (blood vessel growth), lymphangiogenesis (lymphatic vessel growth) and vascular leakage for the treatment of ophthalmic diseases.


Opthea's lead compound, OPT-302, is a soluble receptor that specifically and potently blocks the activityof two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, that are involved in the progressionof both retinal and corneal diseases.  

 

Opthea is currently developing OPT-302 for the treatment of wet age-related macular degeneration (wet AMD).

 

Opthea Pty Ltd is a private, 100% owned subsidiary of Circadian Technologies Limited based in Melbourne, Australia.  Enquiries can be directed to: info@opthea.com
 

News

Circadian/Opthea has formed a Clinical Advisory Board (CAB) focused on the development of OPT-302 Read More...

Bioshares Report - OPT-302 for Wet AMD - 17.11.2014 Read More...

Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY), through its 100% owned subsidiary Opthea P Read More...

Email

To receive notifications about Opthea, subscribe to our distribution list.

Twitter